Class Action Signal

Class Action Signal

Class ActionsNews
Class ActionsNewsAboutContact
Public case information

Ultragenyx Pharmaceutical Securities Class Action

Follow to receive email when new source reporting is added to this case. Email delivery also depends on your profile notification settings and a verified email address.

Ultragenyx Pharmaceutical · Setrusumab · Ongoing Litigation

Last updated

Case overview

Defendant company
Ultragenyx Pharmaceutical
Product or service
Setrusumab
Case status
Ongoing Litigation
Lawsuit type
Securities
Reported harm
Misrepresentation

Important dates

Ultragenyx Pharmaceutical class action counsel intake
Ultragenyx lead plaintiff application

Participation information

Availability is based on each listed participation option and its deadline.

Ultragenyx Pharmaceutical class action counsel intake

Purchasers of Ultragenyx common stock between August 3, 2023 and December 26, 2025, inclusive, were invited to contact counsel regarding the filed securities class action. Investors seeking to serve as lead plaintiff had to move the court by April 6, 2026.

Submit the form to contact Rosen Law Firm regarding the class action and potential lead-plaintiff representation.

Type
Law Firm Signup
Status
Deadline passed
Reported proof requirement
Unclear
Submit form regarding the Ultragenyx class action

Ultragenyx lead plaintiff application

Purchasers of Ultragenyx common stock between August 3, 2023 and December 26, 2025, inclusive, were informed of the opportunity to seek appointment as lead plaintiff.

A motion to serve as lead plaintiff had to be filed with the court by April 6, 2026.

Type
Lead Plaintiff
Status
Deadline passed
Reported proof requirement
Unclear
Source article

This information does not determine whether you qualify for a case.

Sources

Public reporting associated with this case.